Skip to main content
. 2007 Jan;170(1):347–355. doi: 10.2353/ajpath.2007.060066

Figure 4.

Figure 4

Analysis of Hh targets and BclII expression after cyclopamine treatment. a: Levels of Gli1 and PTCH1, but not Gli2, are significantly reduced by 5 μmol/L cyclopamine compared with vehicle-treated controls. b: BclII luciferase reporter assays after 5 μmol/L cyclopamine exposure reveal progressive inhibition of BclII expression throughout 30 hours. BclII expression was not inhibited in DAOY cells stably expressing Gli1 (Gli1-5). c: Hedgehog pathway blockade in DAOY and UW228 cells by cyclopamine for 48 hours also inhibited BCL2 protein expression normalized to GAPDH. *P < 0.05, ** P < 0.005 for two-sided t-tests; ns, not significant.